WO2026130272 - ANTI-DLL3/SEZ6 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/130272
Publication Date
25.06.2026
International Application No.
PCT/CN2025/142369
International Filing Date
15.12.2025
Title **
[English]
ANTI-DLL3/SEZ6 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-DLL3/SEZ6 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
YANG, Liu
AN, Wenqian
Priority Data
PCT/CN2024/139506
16.12.2024
CN
PCT/CN2025/078014
19.02.2025
CN
PCT/CN2025/086884
02.04.2025
CN
PCT/CN2025/128458
17.10.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3678 | |
| EPO | Filing, Examination, Granting | 46483 | |
| Japan | Filing, Examination, Granting | 3606 | |
| South Korea | Filing, Examination, Granting | 5360 | |
| USA | Filing, Examination, Granting | 19140 |
Total:
78,267
Contact Us
Abstract[English]
This disclosure provides anti-DLL3 antibodies or antigen binding fragments thereof, antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof) that specifically bind to two different antigens (e.g., DLL3 and SEZ6), and antibody drug conjugates.[French]
La présente divulgation concerne des anticorps anti-DLL3 ou des fragments de liaison à l'antigène de ceux-ci, des constructions de protéine de liaison à l'antigène (par exemple, des anticorps bispécifiques ou des fragments de liaison à l'antigène de ceux-ci) qui se lient de manière spécifique à deux antigènes différents (par exemple, DLL3 et SEZ6), et des conjugués anticorps-médicament.